Vanta Bioscience Ltd
Incorporated in 2016, Vanta Bioscience
Ltd is in the business of Preclinical Activities.[1]
- Market Cap ₹ 15.3 Cr.
- Current Price ₹ 24.3
- High / Low ₹ 56.0 / 19.1
- Stock P/E
- Book Value ₹ 16.5
- Dividend Yield 0.00 %
- ROCE -11.6 %
- ROE -37.2 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 3.45% over last quarter.
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -32.3% over past five years.
- Company has a low return on equity of -27.2% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 466 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 12.08 | 13.75 | 9.82 | 9.40 | 5.83 | 9.72 | 1.96 | |
| 8.81 | 9.38 | 5.87 | 5.93 | 8.22 | 8.41 | 6.21 | |
| Operating Profit | 3.27 | 4.37 | 3.95 | 3.47 | -2.39 | 1.31 | -4.25 |
| OPM % | 27.07% | 31.78% | 40.22% | 36.91% | -40.99% | 13.48% | -216.84% |
| 0.23 | 0.11 | 0.03 | 0.42 | 0.69 | 0.11 | 0.11 | |
| Interest | 1.69 | 1.95 | 2.14 | 2.35 | 5.89 | 5.75 | 4.07 |
| Depreciation | 0.71 | 1.19 | 1.25 | 1.32 | 2.67 | 4.50 | 4.42 |
| Profit before tax | 1.10 | 1.34 | 0.59 | 0.22 | -10.26 | -8.83 | -12.63 |
| Tax % | 36.36% | 24.63% | 23.73% | 40.91% | 1.75% | -2.49% | 5.23% |
| 0.70 | 1.01 | 0.45 | 0.14 | -10.44 | -8.61 | -4.77 | |
| EPS in Rs | 1.11 | 1.58 | 0.71 | 0.14 | -10.27 | -3.68 | -7.56 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -32% |
| 3 Years: | -41% |
| TTM: | -80% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -105% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -33% |
| 3 Years: | -34% |
| 1 Year: | -52% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -13% |
| 3 Years: | -27% |
| Last Year: | -37% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 |
| Reserves | 15.94 | 17.16 | 17.61 | 17.70 | 11.20 | 8.89 | 4.11 |
| 13.25 | 17.37 | 35.97 | 44.86 | 57.16 | 60.95 | 70.09 | |
| 3.51 | 7.74 | 9.74 | 12.53 | 10.04 | 9.25 | 5.37 | |
| Total Liabilities | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 |
| 17.90 | 20.76 | 29.39 | 36.12 | 57.22 | 54.15 | 68.97 | |
| CWIP | 3.70 | 7.00 | 19.34 | 28.47 | 10.60 | 12.53 | 0.00 |
| Investments | 1.95 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 15.46 | 20.82 | 20.90 | 16.81 | 16.89 | 18.72 | 16.91 | |
| Total Assets | 39.01 | 48.58 | 69.63 | 81.40 | 84.71 | 85.40 | 85.88 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| -1.04 | 2.34 | 6.97 | 5.28 | -0.63 | 2.68 | -2.41 | |
| -5.73 | -7.59 | -22.30 | -17.24 | -5.91 | -3.31 | -6.69 | |
| 9.94 | 2.17 | 17.78 | 9.53 | 6.41 | 0.69 | 9.16 | |
| Net Cash Flow | 3.18 | -3.07 | 2.46 | -2.43 | -0.13 | 0.06 | 0.06 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 465.56 |
| Inventory Days | 1,773.25 | ||||||
| Days Payable | 1,345.60 | ||||||
| Cash Conversion Cycle | 47.14 | 36.90 | 74.71 | 43.88 | 122.71 | 117.91 | 893.21 |
| Working Capital Days | 260.76 | 259.61 | 91.06 | -135.13 | -163.40 | -220.80 | -2,126.68 |
| ROCE % | 8.35% | 5.21% | 3.77% | -5.82% | -4.16% | -11.58% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 06.09.2025
6 Sep - Board approved FY2024-25 Annual Report; AGM on Sep 30, 2025 at 10:00 AM; e-voting Sep 27-29.
- Financials For The Half Year And Year Ended 31.03.2025 1 Aug
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 01.08.2025
1 Aug - Vanta Bioscience reports FY25 audited standalone and consolidated results with net losses and unmodified audit opinion.
-
Board Meeting Intimation for Postponement Of Board Meeting To August 01, 2025
29 Jul - Board meeting postponed to Aug 1, 2025; financial results approval delayed; trading window closed till Aug 3.
-
Board Meeting Intimation for Postponement Of Board Meeting To July 29, 2025
26 Jul - Board meeting postponed to July 29, 2025 for approving March 31, 2025 financial results.
Business Overview:[1]
The company is a preclinical contract research organization, offering preclinical safety assessment services for clientele from the Pharmaceutical, Medical Devices, Nutraceuticals, Feed additives, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, the company also provides risk assessment services for evaluating the safety of Active Pharmaceutical Ingredients (API), excipients, extractable and leachable including pharmaceutical impurities resulting due to manufacturing process or degradation
of the product. VBS also provides expert services for the determination of health-based exposure limits e.g. permitted daily exposure or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.
Services Offered:
a) Toxicology[2]
b) Agro-chemical and Chemical Safety[3]
c) Bio Compatibility Studies[4]
d) Diet Formulation[5]
e) Batch Release Test[6]
f) Medical Devices[7]
g) Food Additives[8]
h) Cosmetics[9]